This post was originally published on this site The first patient has been dosed with Hemispherx Biopharma‘s experimental treatment Ampligen (rintatolimod), in combination with Keytruda (pembrolizumab) and cisplatin, for recurrent ovarian cancer. The investigator-sponsored Phase 2 trial (NCT03734692) is expected to treat 45 ovarian cancer patients who responded to platinum-based chemotherapy for at least six months.…

This post was originally published on this site Interim data from an ongoing Phase 1/2 clinical trial show that Celgene’s investigational therapy iberdomide (CC-220), used in combination with dexamethasone, is safe and controlled disease in nearly 90% of multiple myeloma patients who had failed multiple prior treatments. The preliminary findings were discussed in an oral…

This post was originally published on this site MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among those receiving the treatment alone or in combination with Rituxan (rituximab). Further, the data suggest that the…

This post was originally published on this site About a year ago, I wrote about the blackberry patch in my yard. It’s a wild patch, probably started by a squirrel dropping a berry, and it’s full of thorns. But every spring, I see a daffodil pop up through those thorns. Daffodils are a symbol of…

This post was originally published on this site Adding Tecentriq (atezolizumab) to a combination of Avastin (bevacizumab) and chemotherapy cut the risk of death by nearly half in a group of metastatic non-small cell lung cancer (NSCLC) patients with liver metastasis, an exploratory Phase 3 trial analysis shows. The findings were presented at the 2019…

This post was originally published on this site A new partnership between Susan G. Komen and Cancer Australia will grant a researcher $450,000 over three years to study metastatic breast cancer. Through a Career Catalyst Research Grant provided by the International Collaborative Research Partnership, Delphine Merino of La Trobe University in Australia will focus on providing…

This post was originally published on this site Prostate cancer cells can activate genes associated with bone formation and mimic bone cells’ behavior, allowing them to spread into bones. Those findings by by Duke University researchers, have revealed that targeting this transformation process may represent an alternative strategy to prevent the progression and metastization of…

This post was originally published on this site Maintenance treatment with Rubraca (rucaparib) delays the need for additional treatments among women with platinum-sensitive recurrent ovarian cancer — and then extends the time to disease worsening after those subsequent therapies, a Phase 3 trial found. The exploratory analysis from the ARIEL3 Phase 3 trial (NCT01968213) was…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved — with conditions — Genentech‘s Polivy (polatuzumab vedotin-piiq),  used in combination with Rituxan (rituximab) and bendamustine (a chemotherapy), to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had gone through at least two prior therapies. The approval…

This post was originally published on this site Darolutamide in combination with androgen deprivation therapy (ADT) delays disease worsening in men with non-metastatic castration-resistant prostate cancer (nmCRPC) and stabilizes their quality of life without increasing the incidence of adverse events, new data from a Phase 3 trial shows. The findings were presented in an oral…

This post was originally published on this site The investigational immunotherapy AMG 420 lessened tumor burden and led to cancer disappearing in half of the patients with relapsed or refractory multiple myeloma who received the most effective dose in a Phase 1 clinical trial. The study, “Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line therapy for patients with metastatic or recurrent and inoperable head and neck squamous cell carcinoma (HNSCC) whose tumors express the PD-L1 factor. It also approved the treatment in combination with platinum chemotherapy — cisplatin…